Krystal Biotech

Yahoo Finance • 6 days ago

Krystal Biotech, Inc. (KRYS): Promising Pipeline or Risky Gamble?

We recently published a list of 10 Worst Booming Stocks to Buy According to Short Sellers. In this article, we are going to take a look at where Krystal Biotech, Inc. (NASDAQ:KRYS) stands against other worst booming stocks to buy according... Full story

Yahoo Finance • last month

Krystal Biotech's (NASDAQ:KRYS) Earnings Might Be Weaker Than You Think

Investors appear disappointed with Krystal Biotech, Inc.'s (NASDAQ:KRYS) recent earnings, despite the decent statutory profit number. We did some digging and found some worrying factors that they might be paying attention to. View our lat... Full story

Yahoo Finance • 10 months ago

12 Best Genomics Stocks To Buy Now

In this piece, we will take a look at the 12 best genomics stocks to buy now. If you want to skip our introduction to the genomics industry and all the latest trends, then take a look at 5 Best Genomics Stocks To Buy Now. If there's one t... Full story

Yahoo Finance • 10 months ago

Krystal Biotech Announces EMA Validation of Marketing Authorization Application for VYJUVEK for the Treatment of Dystrophic Epidermolysis Bullosa

If approved, ~3,000 people with DEB in the European Union could receive VYJUVEK to treat the underlying cause of the disease for the first time VYJUVEK received Orphan Drug Designation and PRIME designation from the EMA PITTSBURGH, Nov.... Full story

Yahoo Finance • 11 months ago

Krystal Biotech to Present at the Stifel 2023 Healthcare Conference

PITTSBURGH, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseas... Full story

Yahoo Finance • 11 months ago

Krystal Biotech Inc (KRYS) Announces Q3 2023 Financial Results

Krystal Biotech Inc (NASDAQ:KRYS) reported $8.6 million in VYJUVEK U.S. net product revenue for Q3 2023 The company closed the quarter with a strong balance sheet, boasting $598.6 million in cash, cash equivalents, and investments Net inco... Full story

Yahoo Finance • 11 months ago

Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update

•   284 VYJUVEK Patient Start Forms and $8.6 million in VYJUVEK U.S. net product revenue as of the end of the third quarter •   Cohort 1 completed in Phase 1 clinical trial of KB407 for the treatment of CF •   First patient dosed in Phas... Full story

Yahoo Finance • 11 months ago

Krystal Biotech to Report Third Quarter 2023 Financial Results on November 6, 2023

PITTSBURGH, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat diseas... Full story

Yahoo Finance • last year

Krystal Biotech to Present at the Chardan 7th Annual Genetic Medicines Conference

PITTSBURGH, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization of genetic medicines to treat disea... Full story

Yahoo Finance • last year

Krystal Biotech Announces Orphan Drug Designation Granted to KB408 for the Treatment of Alpha-1 Antitrypsin Deficiency

KB408 IND filed on August 15, 2023 PITTSBURGH, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and commercialization... Full story

Yahoo Finance • last year

Krystal Biotech Announces Sale of Priority Review Voucher for $100 Million

PITTSBURGH, Aug. 21, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ: KRYS) (the “Company”), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines to treat disea... Full story

Yahoo Finance • last year

Arbutus Appoints Two New Executives

Karen Sims, MD, PhD Promoted to Chief Medical Officer Christopher Naftzger Appointed as General Counsel and Chief Compliance Officer WARMINSTER, Pa., July 10, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbu... Full story

Yahoo Finance • last year

Krystal Biotech Announces First Patient Dosed in Phase 1 Clinical Trial of KB407 for the Treatment of Cystic Fibrosis

PITTSBURGH, July 03, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with debilitating diseases, announced to... Full story

Yahoo Finance • last year

Krystal Biotech Announces Clinical Data on Topical Application of B-VEC to the Eye to Treat Ocular Complications in a Patient with Dystrophic Epidermolysis Bullosa Under a Compassionate Use Program

Data presented at Association for Research in Vision and Ophthalmology Annual Meeting on April 23, 2023 Topical application of B-VEC to the eye was well tolerated and patient showed significant improvement of visual acuity and complete cor... Full story

Yahoo Finance • last year

Jeune Aesthetics Announces Dosing of First Subject in Phase 1, Cohort 3 Study of KB301 for the Improvement of Lateral Canthal Lines at Rest

PITTSBURGH, April 18, 2023 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly-owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS), today announced treatment of the first subject in the Phase 1, Cohort 3 study... Full story

Yahoo Finance • last year

Krystal Biotech to Present at Association for Research in Vision and Ophthalmology Annual Meeting

Clinical data on the compassionate use of B-VEC to treat a RDEB patient, with recurrent cicatrizing conjunctivitis that leads to conjunctival scarring, at the Bascom Palmer Eye Institute PITTSBURGH, April 13, 2023 (GLOBE NEWSWIRE) -- Kr... Full story

Yahoo Finance • 2 years ago

Krystal Biotech Appoints Catherine Mazzacco to Board of Directors

PITTSBURGH, March 06, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, today announced the... Full story

Yahoo Finance • 2 years ago

Krystal Biotech to Present at the 43rd Annual TD Cowen Health Care Conference

PITTSBURGH, March 02, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that... Full story

Yahoo Finance • 2 years ago

Krystal Biotech Announces Fourth Quarter and Full Year 2022 Financial Results and Operational Progress

• B-VEC PDUFA date May 19, 2023 • Data from the pivotal Phase 3 (GEM-3) trial of B-VEC for dystrophic epidermolysis bullosa published in the New England Journal of Medicine • Four pipeline clinical trials in dermatology, respiratory and... Full story

Yahoo Finance • 2 years ago

Krystal Biotech Receives European Commission Orphan Designation for KB407 for the Treatment of Cystic Fibrosis

PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases, announced today that... Full story